EUVIMEDEUVIMED entdecken
Crossref

Cell Cycle Progression Score Identifies Biopsy‐Undetected Grade Group 5 Prostate Cancer

Yu Ozawa iD, Marcio Covas Moschovas, Marco Sandri iD, Rohan Sharma, Shady Saikali iD, Travis Rogers, Vipul Patel

The Prostate · 2025

DOI: 10.1002/pros.70112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Yu Ozawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: AdventHealth Global Robotics Institute, Celebration, Florida, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Cell Cycle, Prostate. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Grade Group 5 (GG5) prostate cancer carries the poorest prognosis, yet it is often undetected at biopsy. We evaluate whether Cell Cycle Progression (CCP) score identifies biopsy‐undetected GG5 disease and improves risk stratification when combined with Cancer of the Prostate Risk Assessment (CAPRA) score.

Methods

A total of 430 patients with biopsy‐confirmed GG1–4 underwent Prolaris® testing before immediate radical prostatectomy (RP). Logistic regression assessed the association between CCP score and pathological GG5 at RP. Predictive models using CCP, CAPRA, and clinical cell‐cycle risk (CCR) score were compared using area under the curve (AUC), decision curve analysis (DCA), and net reclassification improvement (NRI).

Results

Although GG5 was not frequent (7.2%), CCP score independently predicted GG5 ( p < 0.001) before and after adjusting for CAPRA and biopsy core number obtained. AUCs were 0.71 (95% CI: 0.60–0.83) for CCP, 0.67 (0.56–0.77) for CAPRA, 0.77 (0.67–0.87) for CCP + CAPRA, and 0.74 (0.64–0.84) for CCR. Both CCP + CAPRA and CCR outperformed CAPRA (DeLong's test, p = 0.008 and 0.001, respectively). DCA showed greater net benefit for CCP + CAPRA at thresholds 0.05–0.50 and for CCR at 0.05–0.40. CCR score yielded a higher overall NRI of 0.90 (95% CI: 0.55–1.20), improving classification for both events and non‐events. A significant positive CCP–CAPRA interaction was identified: GG5 was observed in 5.7% (24/421) of patients with CCP ≤ 4.6 and/or CAPRA ≤ 4, versus 78% (7/9) with both > 4.6 and ≥ 5 ( p = 0.039).

Conclusions

Our data suggests that CCP score adds value to initial risk assessment, particularly in CAPRA‐defined low‐ to favorable‐intermediate‐risk patients. An elevated CCP score should prompt counseling on the increased risk of biopsy‐undetected GG5 disease and consideration of intensified management, such as RP or radiotherapy with prolonged androgen deprivation therapy within a multimodal framework. This is especially relevant in non‐surgical settings where final pathology is unavailable. Clinical Trial Registration: N/A.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCell CycleProstateHumansMaleMiddle AgedAgedNeoplasm GradingProstatectomyBiopsyRisk AssessmentPrognosisDisease Progression

Stichwörter der Autor:innen

Cancer of the Prostate Risk Assessment scoreGleason score 9–10biopsy undergradingclinical cell‐cycle risk scoregenomic classifierrisk stratification

Autor:innen und Institutionen

  • AdventHealth Global Robotics Institute, Celebration, Florida, USA.
  • Urology Department, University of Central Florida (UCF), Orlando, Florida, USA.
  • Big and Open Data Innovation Laboratory (BODaI-Lab), University of Brescia, Brescia, Italy.

ORCID-Profile: Yu Ozawa, Marco Sandri, Shady Saikali

Zitieren

APA

Ozawa, Y., Moschovas, M. C., Sandri, M., Sharma, R., Saikali, S., Rogers, T., & Patel, V. (2025). Cell Cycle Progression Score Identifies Biopsy‐Undetected Grade Group 5 Prostate Cancer. The Prostate. https://doi.org/10.1002/pros.70112

Vancouver

Ozawa Y, Moschovas MC, Sandri M, Sharma R, Saikali S, Rogers T, et al. Cell Cycle Progression Score Identifies Biopsy‐Undetected Grade Group 5 Prostate Cancer. The Prostate. 2025. doi:10.1002/pros.70112

BibTeX
@article{Ozawa2025,
  author = {Ozawa, Yu and Moschovas, Marcio Covas and Sandri, Marco and Sharma, Rohan and Saikali, Shady and Rogers, Travis and Patel, Vipul},
  title = {Cell Cycle Progression Score Identifies Biopsy‐Undetected Grade Group 5 Prostate Cancer},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.70112}
}
Kostenlos starten →